Cytospire Therapeutics
Biotech / immuno-oncology, London
Develops pan-gamma delta T cell engagers for cancer treatment. It raised £61m in its Series A in May 2026. We can't read its job board yet.
Backed by 4BIO Capital, Abingworth, Servier Ventures and Sound Bioventures.
On the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
All 8 stories- LeadershipBioSpace, 8 Sept 2026Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
- OtherServier, 12 May 2026Servier Ventures selects Cytospire Therapeutics for its first investment
- OtherBioCentury, 6 May 2026Cytospire: Broadening tumor killing with pan-γδ T cell engagers
- OtherGlobeNewswire, 5 May 2026Cytospire Therapeutics announces oversubscribed £61 million
- OtherOncodaily, 5 May 2026$83M to Unlock a New Generation of Cancer Immunotherapies – Cytospire Therapeutics Ltd
- OtherFirstWord, 5 May 2026Cytospire banks £61M to test pan-gamma delta engager approach for cancer